St. Vincent's Hospital Sydney Limited

Newsouth Innovations Pty Limited

Centenary Institute of Cancer Medicine and Cell Biology

Csl Behring Gene Therapy, Inc.

Csl Gene Therapy Pty Ltd.

Calimmune, Inc.

Calimmune Australia Pty Ltd

Anthony Dominic Kelleher

John James Zaunders

Nabila Seddiki

Geoffrey Phillip Symonds

Alan Lee Landay

Kazuo Suzuki

Sarah Christina Sasson

Barbara Denise Fazekas De St Groth

Chantelle Lisa Evelyn Ahlenstiel

The present disclosure provides compositions (i.e., amplification primers and probes), methods, and kits that are particularly useful for detecting and/or quantifying nucleic acids present in a sample, such as those derived from HIV or a lentiviral vector.

Methods for discriminating between HIV-1 and lentiviral vectors

The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells.

Kit for identifying regulatory T cells

A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy.

Method for identifying antigen-specific regulatory T cells

The present invention comprises a method for the quantitative or qualitative detection of antigen-specific CD4+ T cells and/or CD8+ T cells in a subject, said method comprising quantitatively or qualitatively detecting the expression of cell surface marker CD25 and one or more of cell surface markers CD134 and CD137 in a suitable lymphocyte-containing sample from said subject in response to exposure to an antigen. A method for determining the immunocompetence of a subject and a method for isolating antigen-specific CD4+ and/or CD8+ T cells is also disclosed.

Method for detecting antigen specific or mitogen-activated T cells

Method for identifying regulatory T cells

Growing community of inventors

Bangor, Australia

Anthony Dominic Kelleher